GNLX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Genelux Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.17 |
52 Week High | US$30.44 |
52 Week Low | US$1.60 |
Beta | 0 |
11 Month Change | 11.28% |
3 Month Change | -19.93% |
1 Year Change | -90.60% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -64.72% |
Recent News & Updates
Shareholder Returns
GNLX | US Biotechs | US Market | |
---|---|---|---|
7D | -4.0% | 0.9% | 0.3% |
1Y | -90.6% | 15.2% | 22.2% |
Return vs Industry: GNLX underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: GNLX underperformed the US Market which returned 22.2% over the past year.
Price Volatility
GNLX volatility | |
---|---|
GNLX Average Weekly Movement | 14.3% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNLX's share price has been volatile over the past 3 months.
Volatility Over Time: GNLX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 24 | Tom Zindrick | www.genelux.com |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer.
Genelux Corporation Fundamentals Summary
GNLX fundamental statistics | |
---|---|
Market cap | US$67.52m |
Earnings (TTM) | -US$26.54m |
Revenue (TTM) | US$8.00k |
9,250x
P/S Ratio-2.8x
P/E RatioIs GNLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GNLX income statement (TTM) | |
---|---|
Revenue | US$8.00k |
Cost of Revenue | US$0 |
Gross Profit | US$8.00k |
Other Expenses | US$26.55m |
Earnings | -US$26.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.78 |
Gross Margin | 100.00% |
Net Profit Margin | -331,725.00% |
Debt/Equity Ratio | 0% |
How did GNLX perform over the long term?
See historical performance and comparison